Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:


Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,795,745

« Back to Dashboard

Title: Human growth hormone
Abstract:Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
Inventor(s): Goeddel; David V. (Burlingame, CA), Heyneker; Herbert L. (Burlingame, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Filing Date:Jun 01, 1995
Application Number:08/457,282
Claims:1. A method of producing a polypeptide of known amino acid sequence by constructing a replicable cloning vehicle containing DNA encoding said polypeptide, said cloning vehicle contained within a microbial organism, wherein said DNA is under the control of an expression promotor contained in said replicable cloning vehicle, comprising:

a) obtaining by reverse transcription from messenger RNA a first DNA fragment for an expression product other than said polypeptide, which fragment comprises at least a substantial portion of the coding sequence for said polypeptide;

b) where the first fragment comprises protein-encoding codons for amino acid sequences other than those contained in said polypeptide, eliminating the same while retaining at least a substantial portion of said coding sequence, the resulting fragment nevertheless coding for an expression product other than said polypeptide;

the product of step (a) or, where required, step (b) being a fragment encoding less than all of the amino acid sequence of said polypeptide;

c) providing by organic synthesis one or more DNA fragments encoding the remainder of the amino acid sequence of said polypeptide, at least one of said fragments coding for the amino-terminal portion of the polypeptide; and

d) deploying the synthetic DNA fragment(s) of step (c) and that produced in step (a) or (b), as the case may be, in a replicable cloning vehicle in proper reading phase relative to one another and under the control of an expression promoter;

whereby a replicable cloning vehicle capable of expressing the amino acid sequence of said polypeptide is formed; and

e) expressing said DNA to produce said polypeptide.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.